Navigation Links
Althea Technologies Acquires Altus Pharmaceuticals'(R) Assets and IP Portfolio, Establishing Technology Platform for Protein Formulations.
Date:5/2/2010

SAN DIEGO, May 2 /PRNewswire/ -- Althea Technologies, Inc., a leading provider of services for biopharmaceutical development and manufacturing announced today that it has acquired the assets and IP portfolio of Altus Pharmaceuticals. The IP portfolio includes, among other things, Altus' Cross Linked Enzyme Crystal (CLEC®) and controlled release injectable technologies.  Applications of this protein crystal technology range from therapeutics to protein purification and catalysis. The controlled release injectable technology involves protein crystallization and complexation using customized manufacturing equipment installed at Althea.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20020925/LAW010LOGO)

Additionally, the assets encompass a portfolio of product candidates based on these technologies which includes a seven day controlled release growth hormone injectable which has completed a phase 2 clinical trial. Althea was the manufacturer of the clinical supplies for this product candidate. Althea plans to enter into licensing discussions for these product candidates.

"We are delighted to acquire this portfolio of technologies which complements our core expertise in protein formulation and will bring added value to our customers' projects," commented Dr. Shabbir Anik, CEO of Althea Technologies. "We expect multiple applications for a broad range of proteins, peptides and vaccines addressing the need for controlled release, high concentration formulations, and stability," he added.

Althea will be exhibiting at the BIO International Convention: Booth #5940.

About Althea Technologies, Inc.

Althea Technologies is a fully integrated, contract development and manufacturing organization that provides services for plasmids, protein biologics and sterile products. Located in San Diego, CA, Althea offers cell banking, process development, cGMP protein & plasmid production, analytical development, formulation development, aseptic filling in vials & prefilled syringes, and lyophilization services for clinical development and commercialization.  For more information, visit www.altheatech.com.


'/>"/>
SOURCE Althea Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services
2. China Medical Technologies to Announce Results for the Fourth Fiscal Quarter and the Fiscal Year Ended March 31, 2010 on June 4, 2010
3. China Medical Technologies to Participate in Investor Conferences in May and June 2010
4. CareFusion, Cerner to Integrate Technologies for Improved Hospital Safety, Efficiency
5. Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award
6. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
7. MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation
8. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
9. Abbott Completes Acquisition of STARLIMS Technologies
10. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
11. Rauland-Borg and Visonic Technologies Collaboration Brings Enhanced RTLS Functionality to the Responder 5(R) Nurse Call System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):